Stock analysts at Maxim Group started coverage on shares of Cellular Biomedicine Group Inc. (NASDAQ:CBMG) in a research note issued to investors on Thursday. The firm set a “buy” rating and a $16.00 price target on the stock. Maxim Group’s price objective suggests a potential upside of 11.65% from the stock’s current price.

Cellular Biomedicine Group (NASDAQ:CBMG) opened at 14.33 on Thursday. The firm’s market cap is $202.08 million. Cellular Biomedicine Group has a 12 month low of $10.44 and a 12 month high of $25.20. The stock’s 50 day moving average is $14.17 and its 200 day moving average is $15.40.

About Cellular Biomedicine Group

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Cellular Biomedicine Group, Inc (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.

5 Day Chart for NASDAQ:CBMG

Receive News & Ratings for Cellular Biomedicine Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group Inc. and related companies with's FREE daily email newsletter.